M3541 in Combination With Radiotherapy in Subjects With Solid Tumors
Status:
Completed
Trial end date:
2020-04-27
Target enrollment:
Participant gender:
Summary
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetic (PK),
pharmacodynamic, and explore antitumor activity of M3541 in combination with fractionated
palliative radiotherapy (RT) in subjects with solid tumors with malignant lesions in the
thorax, abdominal cavity, head and neck region, or extremities likely to benefit from
palliative RT.